Cochlear Limited (COH.AX) vs Mesoblast Limited (MESO)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| COH.AX | MESO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
| Size band | MID | SMALL |
| Listing | ASX | Nasdaq GS |
| Country | Australia | Australia |
| Theme | medical-devices | cell-therapy |
| Price and returns | ||
| Last close | 141.82 AUD | $12.39 |
| Return · 1 week | +1.74% | +3.68% |
| Return · 1 month | −2.28% | −14.55% |
| Return · 3 months | +15.77% | −14.26% |
| Return · year to date | −44.98% | −31.77% |
| Return · 1 year | −50.24% | −25.85% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −52.17% | −42.37% |
| 52-week high | 296.50 AUD | $21.50 |
| 52-week low | 88.74 AUD | $11.89 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $6.51B | $1.61B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $57.69M | $2.36M |
| Employees | 5,400 | 108 |
| Valuation | ||
| Price to earnings · trailing | 62.76× | n/a (negative earnings) |
| Price to earnings · forward | 24.75× | 31.41× |
| Price to sales | 3.92× | 15.43× |
| Price to book | 5.28× | 3.26× |
| Enterprise value to EBITDA | 19.33× | n/a (negative EBITDA) |
| Enterprise value to revenue | 3.95× | 15.28× |
| PEG ratio | 3.08 | — |
| Earnings per share · trailing | 2.24 | -0.44 |
| Profitability | ||
| Gross margin | 70.69% | 86.14% |
| Operating margin | 14.33% | −33.28% |
| Profit margin | 6.27% | −47.82% |
| Return on equity | 7.98% | −9.86% |
| Return on assets | 9.71% | −4.11% |
| Growth | ||
| Revenue growth | +0.80% | +390.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 12.22 | 22.40 |
| Current ratio | 2.15 | 2.44 |
| Dividend yield | 1.84% | 0.00% |
| Payout ratio | 190.94% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 58.94 | 35.89 |
| ADX · 14 | 26.37 | 24.55 |
| 50-day average | 136.46 AUD | $15.15 |
| 200-day average | 149.08 AUD | $15.50 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.85% | 4.40% |
The full COH.AX analysis
Everything this table leaves out for Cochlear Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the COH.AX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full COH.AX analysisThe full MESO analysis
Everything this table leaves out for Mesoblast Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MESO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MESO analysis